# A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma

> **NCT06245551** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 64 (actual)

## Conditions studied

- Asthma, Exercise-Induced

## Interventions

- **DRUG:** Budesonide/albuterol metered-dose inhaler 160/180 μg
- **DRUG:** Placebo metered-dose inhaler

## Key facts

- **NCT ID:** NCT06245551
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-22
- **Primary completion:** 2024-06-29
- **Final completion:** 2024-06-29
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06245551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06245551, "A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06245551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*